Seborrheic dermatitis is a common skin condition that causes redness, itching, and flaking, particularly in areas with high concentrations of oil glands, such as the scalp and face. Treatment options for seborrheic dermatitis may include medicated shampoos, topical creams, and other dermatological products.
Latest Seborrheic dermatitis Companies UpdateSeptember 2023: Zoryve, a topical formulation of roflumilast foam 0.3% licensed by the Food and Drug Administration, is attempting to show that it is more than just an itch reliever. The late-stage roflumilast foam data was unveiled by Arcutis in the seborrheic dermatitis study. This is a chronic inflammatory skin illness that the medicine is being tested for in adults and children with moderate to severe cases, ranging in age from nine years and above. In the first quarter of 2023, Arcutis plans to submit roflumilast foam for FDA clearance, armed with favorable data from the late-stage STRATUM research. With an investigator global assessment (IGA) score of clear or almost clear and a level grade 2 or greater improvement from baseline on the same metric, 80.1% of patients on roflumilast foam achieved investigator global assessment (IGA) success in the 457-subject trial, allowing the study to hit its primary endpoint. In contrast, just 59.2% of individuals who received a placebo cream achieved success on the identical assessment.List of Seborrheic dermatitisKey companies in the market
Seborrheic Dermatitis Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)